Matinas Biopharma
MTNB

Matinas Biopharma (MTNB) earnings history

Most recent quarter

Period end
Sep 30, 2024
EPS actual
−$0.85
EPS estimate
−$1.06
Revenue
$0.00
Reported
Nov 13, 2024

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q3 2024Nov 13, 2024−$1.06−$0.85+19.43%$0.00SEC
Q2 2024Aug 14, 2024−$1.25−$1.00+20.00%$0.00SEC
Q1 2024May 9, 2024−$1.50−$1.50+0.00%$0.00SEC
Q4 2023Mar 27, 2024−$1.50−$1.00+33.33%$0.00SEC
Q3 2023Nov 8, 2023−$1.45−$1.50−3.27%$0.00SEC
Q2 2023Aug 9, 2023−$1.52−$1.50+1.15%$0.00SEC
Q1 2023May 10, 2023−$1.50−$1.50+0.00%$1.1MSEC
Q4 2022Mar 15, 2023−$1.27−$1.00+20.95%$1.1MSEC
Q3 2022Nov 2, 2022−$1.48−$1.50−1.09%$1.1M
Q2 2022Aug 11, 2022−$1.68−$1.50+10.78%$1.1M
Q1 2022May 12, 2022−$1.33−$1.50−12.50%$0.00
Q4 2021Mar 8, 2022−$1.69−$1.50+11.18%$0.00
Q3 2021Nov 8, 2021−$0.97−$1.50−54.24%$0.00
Q2 2021Aug 10, 2021−$1.50−$1.00+33.33%$0.00
Q1 2021May 10, 2021−$1.32−$1.50−13.85%$33,333.00
Q4 2020Mar 29, 2021−$1.39−$1.50−7.68%$62,500.00
Q3 2020Nov 6, 2020−$1.75−$1.50+14.29%$96,000.00
Q2 2020Aug 10, 2020−$1.60−$1.50+6.25%$0.00
Q1 2020May 11, 2020−$1.60−$1.50+6.25%$0.00

Quarterly revenue

Q1 2020
$0.00
Q2 2020
$0.00
Q3 2020
$96,000.00
Q4 2020
$62,500.00
Q1 2021
$33,333.00
Q2 2021
$0.00
Q3 2021
$0.00
Q4 2021
$0.00
Q1 2022
$0.00
Q2 2022
$1.1M
Q3 2022
$1.1M
Q4 2022
$1.1M
Q1 2023
$1.1M
Q2 2023
$0.00
Q3 2023
$0.00
Q4 2023
$0.00
Q1 2024
$0.00
Q2 2024
$0.00
Q3 2024
$0.00

Frequently asked questions

  • When did Matinas Biopharma (MTNB) last report earnings?

    Matinas Biopharma last reported on Nov 13, 2024, covering fiscal Q3 2024.

  • Did MTNB beat earnings estimates?

    Yes. Matinas Biopharma reported EPS of −$0.85 for Q3 2024 against a −$1.06 estimate — a 19.43% beat.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.